J M Vigouret
Overview
Explore the profile of J M Vigouret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borel J, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller E, et al.
Adv Pharmacol
. 1996 Jan;
35:115-246.
PMID: 8920206
No abstract available.
2.
Nozulak J, Vigouret J, Jaton A, Hofmann A, DRAVID A, Weber H, et al.
J Med Chem
. 1992 Feb;
35(3):480-9.
PMID: 1346652
Centrally acting alpha 1-agonists may be of therapeutic value in dementias and other CNS disorders characterized by symptoms of noradrenergic insufficiency. Therefore, on the basis of known peripherally acting alpha...
3.
Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test
Pillon B, Dubois B, Bonnet A, Esteguy M, Guimaraes J, Vigouret J, et al.
Neurology
. 1989 Jun;
39(6):762-8.
PMID: 2725868
To evaluate clinically the slowing of cognitive processing in Parkinson's disease, we used a visual discrimination task consisting of 15 superimposed images of objects. The time needed to identify 12...
4.
Coward D, Dixon A, Urwyler S, Vigouret J
Pharmacopsychiatry
. 1988 Nov;
21(6):312-3.
PMID: 2907635
No abstract available.
5.
Karlsson G, Jaton A, Vigouret J
Neurosci Lett
. 1988 May;
88(1):69-74.
PMID: 2969468
The selective dopamine D2-antagonist sulpiride potentiated contralateral circling behaviour induced by the D1-agonist CY 208-243 in rats with unilateral lesions of substantia nigra, but reduced the effects of the selective...
6.
Giger R, Loosli H, Walkinshaw M, Clark B, Vigouret J
Experientia
. 1987 Oct;
43(10):1125-30.
PMID: 2959497
We report the synthesis, stereochemistry and preliminary pharmacological evaluation of DCN 203-922, a novel ergot alkaloid of the cyclol type, which contains in its peptide moiety the uncommon amino acid...
7.
Markstein R, Enz A, Vigouret J, JATON A, Closse A, Briner U, et al.
J Neural Transm
. 1987 Jan;
69(3-4):179-99.
PMID: 2887630
CK 204-933 displaces [3H]dopamine and [3H]spiperone with high affinity from D-1 and D-2 recognition sites in membranes of calf caudate. Results from functional in vitro tests suggest that it is...
8.
Seiler M, Stoll A, Closse A, Frick W, JATON A, Vigouret J
J Med Chem
. 1986 Jun;
29(6):912-7.
PMID: 3712381
5-Hydroxy-2-aminotetralin derivatives in which one N-alkyl substituent carries a functional group have been prepared and their dopaminergic activities compared with those of 5-hydroxy-2-(di-n-propylamino)tetralin (5-OH-DPAT) and known ergolines. Several members of...
9.
Jaton A, Giger R, Vigouret J, Enz A, Frick W, Closse A, et al.
Life Sci
. 1986 Jan;
38(2):155-63.
PMID: 3003474
The central dopaminergic effects of an abeorphine derivative 201-678 were compared to those of apomorphine and bromocriptine in different model systems. After oral administration, this compound induced contralateral turning in...
10.
Jaton A, Vigouret J
J Pharmacol
. 1985 Jan;
16 Suppl 3:51-6.
PMID: 4094447
Rats were trained in 4 consecutive trials to obtain a liquid reward in a labyrinth system. Drugs were given s.c. 2-4 hours before each trial, and starting time (ST), running...